Therapeutic flag Cosmetic cross-reference

Carbocysteine

CAS 638-23-3

Carbocysteine (CAS 638-23-3) is a Phase 3 pharmaceutical compound with 2 bioactivity targets and 1,093 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
2
SOURCE DrugCentral
Adverse signals
1,093
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Carbocysteine
CAS Number
638-23-3
UNII
740J2QX53R
InChIKey
GBFLZEXEOZUWRN-VKHMYHEASA-N
ChEMBL ID
CHEMBL396416
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
natural producttherapeutic flag
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 3
Late-stage clinical development phase from the compound identifier source.
ChEMBL CHEMBL396416 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE EMBL-EBI ChEMBL 2 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- AC50 29710.144927536232 nM 69 -
- IC50 56500 nM 2 -
SOURCE DrugCentral 80 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Interstitial lung disease 186 219.297 10022611
Hepatic function abnormal 141 189.274 10019670
Pulmonary pain 58 179.644 10074693
Drug ineffective 60 136.283 10013709
Pneumonia 387 127.957 10035664
Pneumonia aspiration 108 124.885 10035669
Upper respiratory tract inflammation 40 115.303 10049590
Lower respiratory tract infection 150 113.85 10024968
Fatigue 64 90.852 10016256
Pneumonia bacterial 55 90.589 10060946
Drug eruption 74 90.279 10013687
Radiation inflammation 23 87.925 10080826
Amyloid arthropathy 18 73.787 10064554
Hyponatraemia 130 72.343 10021036
Platelet count decreased 137 63.996 10035528
Pain 53 62.036 10033371
Pyrexia 304 61.302 10037660
Drug-induced liver injury 70 57.684 10072268
Upper gastrointestinal haemorrhage 54 56.041 10046274
Idiopathic pulmonary fibrosis 24 55.122 10021240
Haemoptysis 61 51.374 10018964
Asthma 103 49.284 10003553
Adrenal suppression 16 46.358 10001382
Dyspnoea 338 45.358 10013968
Cardiac failure 102 45.029 10007554
Malignant neoplasm progression 96 42.59 10051398
Drug hypersensitivity 12 41.646 10013700
Stevens-Johnson syndrome 46 41.361 10042033
Erythema multiforme 31 39.737 10015218
Liver disorder 63 38.128 10024670
Tendonitis 36 37.83 10043255
Infective exacerbation of chronic obstructive airways disease 16 37.477 10056971
Lung neoplasm malignant 40 36.598 10058467
Infective exacerbation of bronchiectasis 11 35.863 10070295
Neutrophil count decreased 68 35.737 10029366
Lip swelling 44 35.613 10024570
Weight increased 13 34.98 10047899
Adjusted calcium decreased 8 34.312 10074757
Infusion related reaction 10 33.939 10051792
Orthostatic hypotension 50 33.641 10031127
Completed suicide 3 33.612 10010144
Pneumothorax 37 33.488 10035759
Toxicity to various agents 24 31.672 10070863
Febrile convulsion 11 31.52 10016284
Sputum retention 11 31.199 10059685
Paraneoplastic rash 7 30.915 10074687
Sputum increased 16 30.682 10041812
Rheumatoid arthritis 10 30.29 10039073
Arthralgia 61 30.159 10003239
Schizophrenia 26 30.065 10039626

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE NLM RxNorm 1 name row

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
carbocysteine 2023 IN RXNORM
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Carbocysteine used for in pharmaceutical contexts?

Carbocysteine (CAS 638-23-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Carbocysteine?

Carbocysteine has 1,093 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Interstitial lung disease, Hepatic function abnormal, Pulmonary pain, Drug ineffective, Pneumonia. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Carbocysteine also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Carbocysteine with EU status "permitted".

What clinical phase is Carbocysteine in?

Carbocysteine is rendered with ChEMBL max phase 3.